Perspectives on long-acting formulations of pre-exposure prophylaxis (PrEP) among men who have sex with men who are non-adherent to daily oral PrEP in the United States
© 2023. BioMed Central Ltd., part of Springer Nature..
INTRODUCTION: Pre-exposure prophylaxis (PrEP) persistence among men who have sex with men (MSM) in real world clinical settings for HIV prevention is suboptimal. New longer-acting formulations of PrEP are becoming available, including injectables, subdermal implants, and other oral medications. These longer-acting formulations have the potential to improve retention among those who have challenges remaining adherent to daily oral PrEP.
METHODS: We interviewed 49 MSM who had initiated but discontinued oral PrEP at three diverse clinics across the United States. We examined participants' perspectives about long-acting PrEP formulations and how long-acting options could affect PrEP use using thematic analysis.
RESULTS: Participants were not very knowledgeable about long-acting formulations of PrEP but were open to learning about them and considering use. Participants were concerned about safety and efficacy of products given that they were still newer and/or in development. Finally, participants had clear preferences for oral pills, injectables, and then subdermal implants and were most interested in options that reduced the number of visits to the clinic.
CONCLUSION: Long-acting formulations of PrEP are acceptable to MSM with suboptimal PrEP persistence and have the potential to improve PrEP persistence. However, many felt they needed more information on safety, efficacy, and use to consider these options. As these long-acting formulations are implemented, public health campaigns and clinical interventions to encourage may maximize uptake particularly among those who are not currently adherent to daily oral PrEP.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
BMC public health - 23(2023), 1 vom: 28. Aug., Seite 1643 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Rogers, Brooke G [VerfasserIn] |
---|
Links: |
---|
Themen: |
HIV prevention |
---|
Anmerkungen: |
Date Completed 31.08.2023 Date Revised 21.11.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12889-023-16382-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM361390165 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM361390165 | ||
003 | DE-627 | ||
005 | 20231226085033.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12889-023-16382-4 |2 doi | |
028 | 5 | 2 | |a pubmed24n1204.xml |
035 | |a (DE-627)NLM361390165 | ||
035 | |a (NLM)37641018 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Rogers, Brooke G |e verfasserin |4 aut | |
245 | 1 | 0 | |a Perspectives on long-acting formulations of pre-exposure prophylaxis (PrEP) among men who have sex with men who are non-adherent to daily oral PrEP in the United States |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 31.08.2023 | ||
500 | |a Date Revised 21.11.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. BioMed Central Ltd., part of Springer Nature. | ||
520 | |a INTRODUCTION: Pre-exposure prophylaxis (PrEP) persistence among men who have sex with men (MSM) in real world clinical settings for HIV prevention is suboptimal. New longer-acting formulations of PrEP are becoming available, including injectables, subdermal implants, and other oral medications. These longer-acting formulations have the potential to improve retention among those who have challenges remaining adherent to daily oral PrEP | ||
520 | |a METHODS: We interviewed 49 MSM who had initiated but discontinued oral PrEP at three diverse clinics across the United States. We examined participants' perspectives about long-acting PrEP formulations and how long-acting options could affect PrEP use using thematic analysis | ||
520 | |a RESULTS: Participants were not very knowledgeable about long-acting formulations of PrEP but were open to learning about them and considering use. Participants were concerned about safety and efficacy of products given that they were still newer and/or in development. Finally, participants had clear preferences for oral pills, injectables, and then subdermal implants and were most interested in options that reduced the number of visits to the clinic | ||
520 | |a CONCLUSION: Long-acting formulations of PrEP are acceptable to MSM with suboptimal PrEP persistence and have the potential to improve PrEP persistence. However, many felt they needed more information on safety, efficacy, and use to consider these options. As these long-acting formulations are implemented, public health campaigns and clinical interventions to encourage may maximize uptake particularly among those who are not currently adherent to daily oral PrEP | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a HIV prevention | |
650 | 4 | |a Medication adherence | |
650 | 4 | |a Men who have sex with men (MSM) | |
650 | 4 | |a PrEP continuum | |
650 | 4 | |a Pre-exposure prophylaxis (PrEP) | |
700 | 1 | |a Chan, P A |e verfasserin |4 aut | |
700 | 1 | |a Sutten-Coats, C |e verfasserin |4 aut | |
700 | 1 | |a Zanowick-Marr, A |e verfasserin |4 aut | |
700 | 1 | |a Patel, R R |e verfasserin |4 aut | |
700 | 1 | |a Mena, L |e verfasserin |4 aut | |
700 | 1 | |a Goedel, W C |e verfasserin |4 aut | |
700 | 1 | |a Chu, C |e verfasserin |4 aut | |
700 | 1 | |a Silva, E |e verfasserin |4 aut | |
700 | 1 | |a Galipeau, D |e verfasserin |4 aut | |
700 | 1 | |a Arnold, T |e verfasserin |4 aut | |
700 | 1 | |a Gomillia, C |e verfasserin |4 aut | |
700 | 1 | |a Curoe, K |e verfasserin |4 aut | |
700 | 1 | |a Villalobos, J |e verfasserin |4 aut | |
700 | 1 | |a Underwood, A |e verfasserin |4 aut | |
700 | 1 | |a Sosnowy, C |e verfasserin |4 aut | |
700 | 1 | |a Nunn, Amy S |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC public health |d 2001 |g 23(2023), 1 vom: 28. Aug., Seite 1643 |w (DE-627)NLM111200962 |x 1471-2458 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:28 |g month:08 |g pages:1643 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12889-023-16382-4 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 23 |j 2023 |e 1 |b 28 |c 08 |h 1643 |